癌症药物开发商 Leap Therapeutics 看到一位大股东抛售了他的大部分股票，但该公司的盈利超出了预期。 Leap Therapeutics, a cancer drug developer, saw a major shareholder sell off most of his stocks, yet the company beat earnings expectations.

生物制药公司Leap Therapeutics公司正在开发抗体治疗癌症, 关键股东Knott David M Jr将其股票持有量减少了63.8%, 达到68000美元. Leap Therapeutics, Inc., a biopharmaceutical company developing antibody therapies for cancer, saw a key shareholder, Knott David M Jr, reduce his stock holdings by 63.8% to $68,000. 该公司的短期利息在3月下降了18.5%,机构投资者拥有30.46%的股票。 The company's short interest declined by 18.5% in March, with institutional investors owning 30.46% of the stock. Leap Therapeutics 最近公布的收益超出分析师预期，每股亏损 0.37 美元。 Leap Therapeutics recently reported earnings that beat analyst expectations, with a loss of $0.37 per share.